| scholarly article | Q13442814 |
| P2093 | author name string | Sheng-Chu Kuo | |
| Tur-Fu Huang | |||
| Jin-Cherng Lien | |||
| Shiu-Wen Huang | |||
| P2860 | cites work | VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 |
| Broad targeting of angiogenesis for cancer prevention and therapy | Q27002903 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation | Q28240025 | ||
| Anthraquinones isolated from Cassia tora (Leguminosae) seed show an antifungal property against phytopathogenic fungi | Q44989505 | ||
| Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation | Q47745076 | ||
| Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. | Q51070538 | ||
| The scientific contributions of M. Judah Folkman to cancer research. | Q53137568 | ||
| Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation | Q73441800 | ||
| 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro | Q74060959 | ||
| Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells | Q74232904 | ||
| Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation | Q79286092 | ||
| Anthracycline and anthraquinone anticancer agents: current status and recent developments | Q28244431 | ||
| Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis | Q28535457 | ||
| NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis | Q28592186 | ||
| VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding | Q28646414 | ||
| VEGF receptor signalling - in control of vascular function | Q29617256 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| Tumorigenesis and the angiogenic switch | Q29619849 | ||
| A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway | Q33443586 | ||
| Role of Akt signaling in vascular homeostasis and angiogenesis | Q34712853 | ||
| PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling | Q34914220 | ||
| Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling | Q35018349 | ||
| WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase 1 | Q35238403 | ||
| Protein kinase inhibitors: insights into drug design from structure. | Q35697409 | ||
| Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis | Q35791487 | ||
| Vascular endothelial growth factor as a target for anticancer therapy | Q35792723 | ||
| Angiogenesis: update 2005. | Q36230890 | ||
| Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis | Q36371903 | ||
| Mechanisms of adverse effects of anti-VEGF therapy for cancer | Q36609627 | ||
| Anti-cancer properties of anthraquinones from rhubarb | Q36615073 | ||
| Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery | Q36670473 | ||
| Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. | Q36869441 | ||
| Migratory neighbors and distant invaders: tumor-associated niche cells | Q37100566 | ||
| Src and focal adhesion kinase as therapeutic targets in cancer | Q37215683 | ||
| FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? | Q37333639 | ||
| The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. | Q37832021 | ||
| Tumor angiogenesis and anti-angiogenic therapy | Q38023701 | ||
| Angiogenesis in cancer: Anti-VEGF escape mechanisms | Q38389975 | ||
| A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway | Q38977013 | ||
| Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling | Q39375920 | ||
| Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation | Q39497489 | ||
| Novel benzimidazole derivatives as expected anticancer agents. | Q39499263 | ||
| Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. | Q39969391 | ||
| Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability | Q41714210 | ||
| Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. | Q42807217 | ||
| Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact | Q43077944 | ||
| Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. | Q43609707 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 39 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| colorectal carcinoma | Q25493920 | ||
| colorectal cancer | Q188874 | ||
| P304 | page(s) | 63124-63137 | |
| P577 | publication date | 2016-08-09 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling | |
| P478 | volume | 7 |
| Q46763062 | Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway |
| Q37702605 | NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway |
| Q33761677 | miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway |
Search more.